Status:
COMPLETED
Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder
Lead Sponsor:
AstraZeneca
Conditions:
Anxiety Disorders
Eligibility:
All Genders
66+ years
Phase:
PHASE3
Brief Summary
The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve elderly patients with gene...
Eligibility Criteria
Inclusion
- Male or female patients, 66 years or older, with a documented clinical diagnosis of Generalised Anxiety Disorder (GAD).
- Absence of current episode of major depression.
Exclusion
- The presence of dementia or other mental disorder than GAD.
- Serious suicidal risk, uncontrolled hypertension, substance or alcohol abuse.
- A current diagnosis of cancer or current or past diagnosis of stroke.
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT00389064
Start Date
September 1 2006
End Date
April 1 2008
Last Update
April 4 2012
Active Locations (43)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Fort Myers, Florida, United States
2
Research Site
Gainsville, Florida, United States
3
Research Site
Miami, Florida, United States
4
Research Site
Sarasota, Florida, United States